



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 22, 2019: 5:30 – 8:30 p.m.

- **Executive Session** **5:00 – 6:00**

 - **Introductions and Approval of DUR Board Minutes** **6:00-6:05**
(Public Comment Prior to Board Action)

 - **DVHA Pharmacy Administration Updates** **6:05-6:10**

 - **Medical Director Update** **6:10-6:15**

 - **Follow-up Items from Previous Meetings** **6:15-6:15**

 - **RetroDUR/ProDUR** **6:15-6:15**

 - **Clinical Update: Drug Reviews** **6:15-6:15**
(Public comment prior to Board action)

 - **Biosimilar Drug Reviews**
 - None at this time

 - **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)
 - None at this time

 - **New Managed Therapeutic Drug Classes** **6:15-6:15**
(Public comment prior to Board action)
 - None at this time

 - **Therapeutic Drug Classes – Periodic Review** **6:15-6:15**
(Public comment prior to Board action)
 - None at this time

 - **Review of Newly-Developed/Revised Criteria** **6:15- 8:15**
(Public comment prior to Board action)
- (All changes below will take effect on 1/1/2020)
- ADHD
 - AHF/Factor IX
 - AHF/Factor VIII
 - Alzheimer’s Medications

- Analgesics/NSAIDs Naproxen
- Analgesics/Long-acting Opioids
- Anticoagulants/NOACs
- Antidiabetics/Insulin
- Antihypertensives/Beta Blockers
- Antipsychotics/LAIs
- Botulinum Toxins
- Derm-Atopic Dermatitis
- Derm-Lidocaine Patches
- Derm-Scabicides
- Endometriosis
- GI-Mesalamine (Oral and Rectal)
- Hematopoietics-ESA
- Hematopoietics-TPO RA's
- Hereditary Angioedema
- Migraine Products-CGRP Inhibitors
- Ophthalmics/Anti-inflammatories
- Ophthalmic/Antibiotic & Steroid Combinations
- Ophthalmic/Carbonic Anhydrase Inhibitors
- Phosphate Binders
- Resp-Inhaled Anticholinergics
- Urinary Antispasmodics
- Vaginal Anti-infectives

▪ **General Announcements**

8:15 – 8:30

Selected FDA Safety Alerts

FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo)

https://www.fda.gov/drugs/drug-safety-and-availability/fda-review-finds-no-increased-risk-prostate-cancer-parkinsons-disease-medicines-containing?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20on%20medicines%20containing%20entacapone&utm_medium=email&utm_source=Eloqua

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease

https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and?utm_campaign=Hep%20C%20DSC%20liver%20injury&utm_medium=email&utm_source=Eloqua

SOVALDI and HARVONI: New dosage forms and use in pediatric patients 3 years of age to less than 12 years of age

<http://s2027422842.t.en25.com/e/es?s=2027422842&e=250032&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=794ae4ee00af4d12be56b65e3ee2ce12&elqaid=9298&elqat=1>

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20on%20Ib

[rance%20%28palbociclib%29%2C%20Kisqali%20%28ribociclib%29%2C%20and%20Verzenio&utm_medium=email&utm_source=Eloqua](#)

▪ **Adjourn**

8:30